Kala Bio Inc (NAS:KALA)
$ 6.7564 -0.1086 (-1.58%) Market Cap: 19.03 Mil Enterprise Value: 4.76 Mil PE Ratio: 0 PB Ratio: 2.52 GF Score: 49/100

Kala Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript

Jan 15, 2020 / 07:30PM GMT
Release Date Price: $274.5 (+4.17%)
Christopher Z. Neyor
JP Morgan Chase & Co, Research Division - Analyst

Chris Neyor from the U.S. pharma team at JPMorgan, and I'm glad to introduce Kala Pharmaceuticals and CEO, Mark Iwicki, here with us today. Kala has 2 exciting products in the dry eye space on its AMPPLIFY platform or rather in the ophthalmology space. That's INVELTYS for postsurgical pain and inflammation launched in 2019 and EYSUVIS for acute dry eye with the pivotal Phase III reading out in 1Q 2020.

We're going to have a presentation from Mark, and then we'll be following up with a breakout session in Elizabethan C next door.

With that, I'll hand it over to Mark.

Mark T. Iwicki
Kala Pharmaceuticals, Inc. - Chairman, President & CEO

Thanks, Chris. Morning, everyone. Thanks for taking the time to be with us this morning. And as Chris said, I'm Mark Iwicki. I'm the CEO of the company. I've been at Kala for almost 5 years. We'll make some forward-looking statements this morning. So here's our appropriate disclaimer and notice about that.

We have a very

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot